Dr Ronnie Fass and colleagues from Arizona determined the value of pH testing in clinical practice in gastroesophageal reflux disease patients who failed anti-reflux treatment.
Of the included patients, 31 were resistant to standard dose proton pump inhibitor or an H2-blocker and underwent pH testing.
| 64% in the proton pump inhibitor failure group had a normal pH test|
|Digestive Diseases & Sciences|
The team randomly selected 70 patients from the proton pump inhibitor failure group, who underwent the modified acid perfusion test.
The research team compared the results to patients with non-erosive reflux disease.
In the proton pump inhibitor failure group, 64% had a normal pH test as compared to 29% in the H2-blocker group.
The team noted that sensory intensity rating were higher in the non-erosive reflux disease control group than the proton pump inhibitor failure group.
The team also observed that acid perfusion sensitivity score was higher in the non-erosive reflux disease control group than the proton pump inhibitor failure group.
Dr Fass' team concludes, “Most patients who continued to be symptomatic on proton pump inhibitor once daily demonstrated a normal pH test, and an overall lack of increased chemoreceptor sensitivity to acid.”